CVRx Inc. Common Stock Q3 2025 Earnings Recap

CVRX Q3 2025 November 6, 2025

Get alerts when CVRX reports next quarter

CVRx posted a strong third quarter with a 10% year-over-year revenue increase, driven by strategic sales force enhancements and expanded commercial reach.

Earnings Per Share Beat

$-0.49 vs $-0.50 est.

+2.0% surprise

Revenue Miss

14690000 vs 15750330 est.

-6.7% surprise

Market Reaction

1-Day +2.66%

5-Day +0.51%

30-Day -3.98%

See CVRX alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue reached $14.7 million, with U.S. sales growing to $13.5 million, reflecting robust heart failure business expansion.
The company onboarded 10 new active implanting centers, bringing the total to 250, alongside a growth in sales territories to 50.
Momentum in adoption of Barostim therapy is underscored by more than 20% of centers performing three or more implants in Q3.
Advancements in reimbursement, including a proposed Category I CPT code effective January 2026, are expected to improve physician payment structures.
A strong presence at the Heart Failure Society of America meeting highlighted growing interest and clinical validation of Barostim therapy.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CVRX on AllInvestView.